BioCentury
ARTICLE | Clinical News

APD421: Phase III data

October 13, 2014 7:00 AM UTC

Pooled data from a total of 626 evaluable surgical patients at moderate to high risk of PONV in a pair of double-blind Phase III trials showed that a single dose of IV APD421 met the primary endpoint ...